OSMF Evidence Tiers
T1 RCT in this condition T2 RCT in related condition T3 Observational in this condition T4 Case series T5 Case report / expert opinion T6 Mechanistic / preclinical only
Direction: Benefit Harm Mixed No benefit (RCT)

Current condition

Long COVID / PASC

Evidence-graded therapeutic interventions for Long COVID / PASC, synthesised from clinical trials, systematic reviews, and mechanistic studies.

Mechanism of Action

Each agent entry includes a molecular-level mechanism description covering key targets, signalling pathways, and proposed disease-relevant mechanisms.

Evidence Tier (T1–T6)

Assigned using the OSMF Evidence Tier framework — T1 = RCT in the target condition; T6 = mechanistic/preclinical only. Tier reflects strongest source.

Key References

Primary trials and publications with citation, DOI, study type, and finding summary — enabling direct access to the underlying evidence.

Registered Trials

Linked ClinicalTrials.gov entries with phase, status, and population — including completed trials and ongoing studies.

This atlas is temporarily offline

The interactive agent grid could not be loaded and is being rebuilt. The same agents, trials and references are available in these pages:

Data Schema

Each agent in the Therapeutics Atlas is structured according to a formal JSON schema, enabling programmatic access, comparison across conditions, and future integration with clinical systems.

name
string
Canonical agent name (INN preferred)
alternateName
string
Brand names, synonyms, abbreviations
mechanism
string
Molecular mechanism of action (1–3 sentences)
mechanismTargets
string[]
Specific molecular targets and pathways
mechanismCategory
string (enum)
Drug class (antiviral, immunomodulator, autonomic…)
direction
"benefit" | "harm" | "null" | "mixed"
Net therapeutic effect direction from evidence
best_tier
integer 1–6
Highest OSMF Evidence Tier across all sources
modifier
string (enum)
NULL | HARM | MIXED | REGISTERED-ONLY
pubchem_cid
integer | null
PubChem Compound ID (small molecules only)
evidence_summary
string
2–3 sentence narrative of evidence base
key_references
object[]
{citation, doi, study_type, finding, year}
key_trials
object[]
{nct_id, title, phase, status, population}

Data Access

While the atlas is offline, the agent data for all conditions is available as machine-readable JSON:

Therapeutic agents JSON ↗

Evidence limitations

This atlas synthesises published evidence as of July 2026. Evidence tiers reflect the best available published evidence per agent-condition pair, not necessarily sufficient evidence for clinical use. T1 RCT data in Long COVID does not always indicate approved indications. All treatment decisions should be made in consultation with qualified healthcare professionals. For conditions like MCAS and ME/CFS where placebo-controlled RCT data is sparse, T2 evidence extrapolated from related conditions forms the evidence base. Trial data should be checked for current status on ClinicalTrials.gov.

Related Resources

Explore biomarker evidence and the full therapeutic pipeline across related conditions.

Biomarker Atlas ME/CFS Biomarkers Long COVID Biomarkers Pipeline Browser

Cite this page

Reusing these data? Please cite the tracker so others can find the source.

Open Source Medicine Foundation. (2026). Therapeutics Evidence Atlas. Research Tracker. https://research.opensourcemed.info/therapeutics-atlas.html (accessed )

Weekly post-viral research digest

New peer-reviewed studies and trial activity across Long COVID, ME/CFS, PACVS, Lyme and Gulf War Illness, every week. Free, no spam.

Subscribe on Substack   Browse the digest archive · RSS